dc.contributor.author |
Sippel, Katherine H.
|
|
dc.contributor.author |
Stander, Andre
|
|
dc.contributor.author |
Tu, Chingkuang
|
|
dc.contributor.author |
Venkatakrishnan, Balasubramanian
|
|
dc.contributor.author |
Robbins, Arthur H.
|
|
dc.contributor.author |
Agbandje-McKenna, Mavis
|
|
dc.contributor.author |
Joubert, Fourie
|
|
dc.contributor.author |
Joubert, Annie M.
|
|
dc.contributor.author |
McKenna, Robert
|
|
dc.date.accessioned |
2012-02-27T07:10:38Z |
|
dc.date.available |
2012-10-31T00:20:03Z |
|
dc.date.issued |
2011-10 |
|
dc.description.abstract |
Sulfamated 2-ethylestra compounds have demonstrated strong anticancer activity, high bioavailability and an ability to bypass liver metabolism by reversibly binding carbonic anhydrase (CA) II in erythrocytes. Another CA isoform, CA IX, is overexpressed in many cancers. The CA domain of CA IX is oriented extracellularly, which may permit targeting inhibitors to tumors. Presented here is the characterization of three 2-ethylestra compounds bound to both CA II and a CA IX mimic protein. Inhibition by 18O exchange showed that compound 16 demonstrated an approximately 12-fold higher affinity for CA II over CA IX mimic. Structurally, compounds 15 and 16 showed alternate binding modes between CA II and CA IX mimic, apparently due to a water-mediated hydrogen bond to the isozyme-specific residue 67. Though the specificity was demonstrated for CA II over CA IX, this study reveals insights that may be key to developing isozyme specific CA inhibitors for novel anticancer therapies. |
en |
dc.description.librarian |
nf2012 |
en |
dc.description.sponsorship |
This work was supported by NIH Grant
GM25154 and by grants from the Medical Research Council of South Africa (AG374, AK076), the Cancer
Association of South Africa (AK246), the Struwig-Germeshuysen Cancer Research Trust of South Africa (AJ038)
and RESCOM University of Pretoria (A0R984). |
en_US |
dc.description.uri |
http://www.benthamscience.com/lddd/ |
en_US |
dc.identifier.citation |
Sippel, KH, Stander, A, Tu, C, Venkatakrishnan, B, Robbins, AH, Agbandje-McKenna, M, Joubert, F, Joubert, AM & McKenna, R 2011, 'Characterization of carbonic anhydrase isozyme specific inhibition by sulfamated 2-ethylestra compounds', Letters in Drug Design & Discovery, vol. 8, no. 8, pp. 678-684. |
en |
dc.identifier.issn |
1570-1808 |
|
dc.identifier.other |
10.2174/157018011796576105 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/18239 |
|
dc.language.iso |
en |
en_US |
dc.publisher |
Bentham Science |
en_US |
dc.rights |
Bentham Science. This article is embargoed by the publisher until October 2012. |
en |
dc.subject |
Structure based drug design |
en |
dc.subject |
2-Ethylestra compounds |
en |
dc.subject |
Anticancer therapy |
en |
dc.subject |
Steroid sulfatase inhibitors |
en |
dc.subject |
Sulfamated 2-ethylestra compounds |
en |
dc.subject |
Liver metabolism |
en |
dc.subject |
Colchicine binding site |
en |
dc.subject |
Anti-angiogenic |
en |
dc.subject |
PISA server |
en |
dc.subject |
CA isoforms |
en |
dc.subject.lcsh |
Carbonic anhydrase |
en |
dc.subject.lcsh |
Isoenzymes |
en |
dc.subject.lcsh |
Drugs -- Design |
en |
dc.subject.lcsh |
Erythrocytes |
en |
dc.subject.lcsh |
Estrogen |
en |
dc.subject.lcsh |
Apoptosis |
en |
dc.subject.lcsh |
Cancer -- Treatment |
en |
dc.title |
Characterization of carbonic anhydrase isozyme specific inhibition by sulfamated 2-ethylestra compounds |
en |
dc.type |
Postprint Article |
en |